NEBION continuously curates COVID-19 related gene expression studies and integrates them into GENEVESTIGATOR®. Using our unique tools, scientists can characterize this disease at the molecular level from multiple perspectives and compare results with thousands of other public datasets.
The following table describes high-quality human and mouse RNA-Seq and microarray studies that have been deeply curated and integrated into GENEVESTIGATOR® for research on COVID-19. Included in this collection are primarily studies investigating molecular changes associated with SARS-CoV-2 infections, as well as secondary studies investigating experimental COVID-19 treatments (repurposed) in the context of their original use.
To learn more about GENEVESTIGATOR® and how you can analyze and visualize this data, visit the GENEVESTIGATOR® website.
|Repository ID (s)
|Number of Samples
|GSE100496/ GSE100504/ GSE100509/ GSE65574/ GSE79172/ GSE79218/ GSE79458/ GSE81909/ GSE86528/ GSE86529/ GSE86530 (part of GSE65575)
|Modeling Host Responses to Understand Severe Human Virus Infections
|RNA-Seq of Human iPSC-cardiomyocytes infected with SARS-CoV-2
|Spectrum of Viral Load and Host Response Seen in Autopsies of SARS-CoV-2 Infected Lungs
|Blocking of the CD80/86 axis as a therapeutic approach to prevent progression to more severe forms of COVID-19
|RV infections in asthmatics increase ACE2 expression and stimulate cytokine pathways implicated in COVID19
|Identification of Lead Drug Candidates for COVID-19 based on Drug Screening Using Human Pluripotent Stem Cell-Derived Cells/Organoids
|Gene expression profiling of SARS-CoV-1 & 2 infected human cell lines at bulk and single-cell level (total RNA)
|Gene expression profiling of SARS-CoV-1 & 2 infected human cell lines at bulk and single-cell level (poly A)
|Primary Human Airway Epithelial Cultures infected with SARS-CoV-2
|Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds
|Generation of human bronchial organoids for SARS-CoV-2 research.
|Bulk RNA sequencing of SARS-CoV and SARS-CoV-2 infected human intestinal organoids.
|Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells against SARS-CoV and DOHV infection.
|GSE47963 (superseries of GSE47960, GSE47961, GSE47962)
|SARS-CoV, SARS-dORF6 and SARS-BatSRBD infection of HAE cultures.
|Cell host-response to infection with novel human coronavirus EMC predict potential antivirals and important differences with SARS-coronavirus
|Cytokine stimulation systems approach demonstrates differences in innate and pro-inflammatory host responses between genetically distinct MERS-CoV isolates.
|SCL006, icSARS CoV Urbani or icSARS Bat SRBD (spike receptor binding domain from the wild type strain Urbani to allow for infection of human and non-human primate cells) infections of the 2B4 clonal derivative of Calu-3 cells - Time course
|SCL005: icSARS CoV Urbani or icSARS deltaORF6 infections of the 2B4 clonal derivative of Calu-3 cells - Time course
|Transcriptional response to SARS-CoV-2 infection
|GSE148817 (part of GSE148818)
|Cell-intrinsic differences between human tracheal epithelial cells from children and adults
|Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study
|Combination of peripheral blood gene expression profiles and clinical parameters predicts response for tocilizumab (anti-IL6) treatment in rheumatoid arthritis
|GSE46293 (Superserie of GSE46280, GSE46282, GSE46283, GSE46292)
|Expression data of multiple sclerosis patients receiving Interferon-beta therapy
|GSE56192 (part of GSE56189)
|Transcriptomic analysis of the Novel Middle East Respiratory Syndrome Coronavirus (Human, MRC5 cells)
|Hepatic gene expression before and during interferon and ribavirin combination therapy
|Effects of tocilizumab versus methotrexate therapy on gene expression profiles in the early rheumatoid arthrtis synovium
|Gene profiling of responders and non-responders to antiviral therapies peg interferon and ribavirin against hepatitis C
|SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues
|Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment
|Host responses contributing to the attenuation of severe acute respiratory syndrome coronaviruses missing E protein domains / GSE52920
|Relative timing of type I interferon response and virus replication determines disease outcome during MERS-CoV infection
|LY6E blocks coronavirus fusion and confers immune control of viral disease
|SM012 - SARS MA15 wild type, and SARS deltaORF6 mutant virus infections of C57BL6 mice - A time course
|Effects of ACE2 on BMPR2 mutation-mediated defects in gene expression
|Expression data of Brain CD11b+ cells from WT and DP1 knockout mice infected with rJ2.2
|Transcriptomic analysis of host response to mouse-adapted SARS virus in wild type, STAT1 -/-, and IFNAR1 -/- mouse genetic backgrounds
|SM004 - SARS infection of C57BL6, TIMP1 and Serpine1 knock-out mice
Table: These human and mouse RNA-Seq and Microarray studies in GENEVESTIGATOR® investigate gene expression changes associated with SARS-CoV-2 and changes associated with experimental treatments of COVID-19.